IC survey

Discussion in 'Lundbeck' started by anonymous, May 13, 2017 at 2:32 AM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    There is a pattern of history with this company of underpaying people and them spinning it that they make mid-year adjustments to correct the matter. You shouldn't have to wait for a screw up and going cheap only results in your risking losing that employee because they will leave many times as someone else will offer them pay that will prompt them to move on.

    So what does it cost to hire and get someone up to speed here.... 50k.....100k?

    Meanwhile we continue to have turnover issues..... LU can't get their shit together. What's the plan? Do we have one? What's the company's commitment to retain talent? Sure seems quiet as usual from senior management.... So much for America driving the company now at 60%.... we sure seem like we have no leadership here.
     

  2. anonymous

    anonymous Guest

    Expect more Neuro AMs to leave. More interviewing with Alexion and other rare disease companies. Besides being underpaid no future for Neuro at this time.
     
  3. anonymous

    anonymous Guest

    America will never drive this company, even if it generates 100% of revenue.
     
  4. anonymous

    anonymous Guest

    Correct, once neuro drugs are gone and only psych left 20%/33%/45% of sales due to terribly negotiated contracts mean Takeda and Otsuka win, Lundbeck loses.